<DOC>
	<DOCNO>NCT02071888</DOCNO>
	<brief_summary>Many tumor cell , contrast normal cell , show require amino acid glutamine produce energy growth survival . To exploit dependence tumor glutamine , CB-839 , potent selective inhibitor first enzyme glutamine utilization , glutaminase , test Phase 1 study patient advance hematologic malignancy . This study open-label Phase 1 evaluation CB-839 subject hematological tumor . Patients receive CB-839 capsule orally two three time daily . The study conduct 2 part . Part 1 dose escalation study identify recommend Phase 2 dose enroll patient advance and/or treatment-refractory Non-Hodgkin 's Lymphoma ( NHL ) , Multiple Myeloma ( MM ) , Waldenström 's macroglobulinemia ( WM ) In Part 2 , patient receive recommended Phase 2 dose . This part enroll patient advanced and/or treatment-refractory Non-Hodgkin 's Lymphoma ( NHL ) , Multiple Myeloma ( MM ) , Waldenström 's macroglobulinemia ( WM ) . All patient assess safety , pharmacokinetics ( plasma concentration drug ) , pharmacodynamics ( inhibition glutaminase ) , biomarkers ( biochemical marker may predict responsiveness later study ) , tumor response . As extension Part 2 , cohort patient relapse refractory MM enrol receive low dose dexamethasone CB-839 . A second cohort patient relapse refractory disease follow least 2 prior treatment regimen enrol receive CB-839 combination standard-dose pomalidomide low-dose dexamethasone evaluate triple combination .</brief_summary>
	<brief_title>Study Glutaminase Inhibitor CB-839 Hematological Tumors</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>DiseaseSpecific Inclusion Criteria Patients must one follow disease either relapse refractory 2 prior treatment : NHL : At least one measurable lesion WM : Measurable IgM , minimum level ≥ 2x ULN MM : Serum Mprotein ≥ 0.5 g/dL and/or urine Mprotein ≥ 200 mg/24 hr . In Part 2 , disease consider measurable per IMWG criterion Other Inclusion Criteria Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 Life Expectancy least 3 month Adequate hepatic , renal , cardiac hematological function Exclusion Criteria Any current malignancy Treatment unapproved , investigational therapeutic agent , immunotherapy biological therapy within 21 day prior first dose study drug Recent bone marrow transplant Unable receive medication mouth Major surgery within 28 day first dose study drug Uncontrolled , active infection ; patient know HIV infection/ seropositivity , Hepatitis A , B , C , CMV reactivation Significant neurotoxicity/neuropathy ( Grade 3 high ) within 14 day prior first dose study drug Refractory nausea vomit situation may preclude adequate absorption Other condition could interfere treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Non-Hodgkin 's lymphoma</keyword>
	<keyword>Waldenstrom 's macroglobulinemia</keyword>
	<keyword>Multiple myeloma</keyword>
	<keyword>glutaminase</keyword>
	<keyword>glutamine</keyword>
</DOC>